This is a working overview of GW501516, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-18. Anything still debated is marked as such rather than presented as settled.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
== External operations == The Selous Scouts were involved in the Rhodesian military's attacks on insurgents and their bases in neighbouring countries, often known as external operations (or 'externals' for short). These operations became frequent from 1976. The unit's role in external operations included intelligence collection and directly attacking insurgents. In the intelligence gathering role, the Selous Scouts' Reconnaissance Troop conducted one or two man long-range reconnaissance patrols to locate or gather information on insurgent bases in Mozambique and Zambia. During direct attacks the Selous Scouts often impersonated soldiers of the country they were operating in. The Selous Scouts operated in eastern Botswana. This included fighting small actions against insurgents and a raid in which ZAPU leaders were captured in Francistown. The Selous Scouts also used pseudo tactics to collect intelligence in Francistown. Operation Long John was launched on 25 June 1976, against two guerilla bases located in Mozambique. This operation used 'flying column' tactics for the first time, which involved six vehicles manned by the Selous Scouts attacking the bases. Large quantities of munitions were destroyed, but few casualties were inflicted. On 9 August 1976, the Selous Scouts carried out Operation Eland, a raid on a ZANLA and FRELIMO controlled refugee camp at Nyadzonia in Mozambique. The Selous Scouts, who were mostly black and disguised in FRELIMO uniforms, included former Portuguese Army soldiers and a former ZANLA commander.
Cephalopods are a diverse group of species, but share common life history traits, for example, they have a rapid growth rate and short life spans. Stearns (1992) suggested that in order to produce the largest possible number of viable offspring, spawning events depend on the ecological environmental factors of the organism. The majority of cephalopods do not provide parental care to their offspring, except, for example, octopus, which helps this organism increase the survival rate of their offspring. Marine species' life cycles are affected by various environmental conditions. The development of a cephalopod embryo can be greatly affected by temperature, oxygen saturation, pollution, light intensity, and salinity. These factors are important to the rate of embryonic development and the success of hatching of the embryos. Food availability also plays an important role in the reproductive cycle of cephalopods. A limitation of food influences the timing of spawning along with their function and growth. Spawning time and spawning vary among marine species; it's correlated with temperature, though cephalopods in shallow water spawn in cold months so that the offspring would hatch at warmer temperatures. Breeding can last from several days to a month.
Alternatively, in Australia Under the Family Law Act 1975 (Cth), a "stepparent" in relation to a child is interpreted as a person who is not a parent of the child and is, or has been, married to or a de facto partner of a parent of the child, and treats, or at any time while married to or a de facto partner of the parent treated, the child as a member of the family formed with the parent. If one member of the couple has prior children but the couple have another child together, the complex/blended designation replaces the "simple" designation upon the birth of the new child. Any subsequent child born to the couple is a half-sibling of the respective members' prior children.
=== Limitations === The phosphine reagents slowly undergo air oxidation in living systems. Additionally, it is likely that they are metabolized in vitro by cytochrome P450 enzymes. The kinetics of the reactions are slow with second order rate constants around 0.0020 M−1•s−1. Attempts to increase nucleophilic attack rates by adding electron-donating groups to the phosphines improved kinetics, but also increased the rate of air oxidation. The poor kinetics require that high concentrations of the phosphine be used which leads to problems with high background signal in imaging applications. Attempts have been made to combat the problem of high background through the development of a fluorogenic phosphine reagents based on fluorescein and luciferin, but the intrinsic kinetics remain a limitation.
Sources: en.wikipedia.org
The assistance of another person in retaining, controlling or using the benefits of drug dealing or criminal conduct under an arrangement (whether by concealment, removal from jurisdiction, transfer to nominees or otherwise) [section 43(1)/44(1)]. The concealment, conversion, transfer or removal from the jurisdiction, or the acquisition, possession or use of benefits of drug dealing or criminal conduct [section 46(1)/47(1)]. The concealment, conversion, transfer or removal from the jurisdiction of another person's benefits of drug dealing or criminal conduct [section 46(2)/47(2)]. The acquirement, possession or use of another person's benefits of drug dealing or criminal conduct [section 46(3)/47(3)].
== History == Golodirsen was developed by collaborative research led by Prof. Steve Wilton and Prof. Sue Fletcher in the Perron Institute and licensed to Sarepta Therapeutics by the University of Western Australia. In the clinical trial of golodirsen, dystrophin levels increased, on average, from 0.10% of normal at baseline to 1.02% of normal after 48 weeks of treatment with the drug or longer. The change was a surrogate endpoint and the trial did not establish clinical benefit of the drug, including changes to the subject's motor function. The pharmacological assessment of golodirsen did not include special population groups, e.g., pregnant and lactating women, the elderly, and people with concurrent disease states. As DMD predominantly affects male children and young adults, and golodirsen is indicated for the treatment of children, but primarily not for adult women, the elderly, and people with comorbidity, it was not evaluated on them. The US Food and Drug Administration (FDA) approved golodirsen in December 2019, under the accelerated approval pathway. The application for golodirsen was granted fast track, priority review, and orphan drug designations, and a rare pediatric disease priority review voucher.
== History == Source distantly originates from the GoldSrc engine, itself a heavily modified version of John Carmack's Quake engine with some code from the Quake II engine. Carmack commented on his blog in 2004 that "there are still bits of early Quake code in Half-Life 2". Valve employee Erik Johnson explained the engine's nomenclature on the Valve Developer Community:
=== Antibody detection === A benefit of antibody detection (ELISA) is that protein identification on a microorganism becomes faster than a western blot. Antibody detection works by attaching an indicator to an antibody with a known specificity and observing whether the antibody attaches. ELISA can also indicate viral presence and is highly specific, having a detection specificity of 10−9-10−12 moles per litre detection. By knowing the epitope sequence of the antibody, ELISA can also be used for antigen detection in a sample.
Following the guidelines of the European institutions, the "adjustment" policy was accompanied by the introduction of three important "structural reforms": the Labor Reform of September 2010 with the purpose of making it more "flexible"; the new law on pensions approved in June 2011 which raised the retirement age from 65 to 67; and the Royal Decree Law, also of June 2011, which "made more flexible" the collective bargaining system. It also raised the general VAT rate from 16 to 18%. The turn in economic policy caused the government to break with the unions who called a general strike for September 29, 2010, the first since Zapatero was in power. Despite all the measures adopted by the government, the risk premium on Spanish debt continued to rise and in the summer of 2011 the situation became unsustainable. Then the European Central Bank decided to act by buying Spanish public debt – and that of other countries with problems, such as Italy— but in exchange it demanded new "structural reforms". The response of Rodríguez Zapatero's government was to proceed quickly with the reform of Article 135 of the Constitution, in which it had the immediate support of the People's Party, to establish the commitment of the State and the autonomous communities not to "incur a structural deficit that exceeds the margins established, where appropriate, by the European Union for its Member States".
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.